Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

168
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
168
T Cell Types and Functions01:24

T Cell Types and Functions

1.0K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.0K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

143
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
143
Inflammatory Response01:28

Inflammatory Response

2.0K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
2.0K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

8.9K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
8.9K
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

130
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
130

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

H3K9me3 regulates IFNγlo Tex cell differentiation to promote colon tumor liver metastasis.

Molecular cancer therapeutics·2026
Same author

A numerical analysis of anti-focus driving to improve focal quality in transvertebral focused ultrasound.

The Journal of the Acoustical Society of America·2026
Same author

Long-term effect of ovary removal on the joints of aged mice.

Laboratory animal research·2026
Same author

Corrigendum: Image-guided ultrasound phased arrays are a disruptive technology for non-invasive therapy (2016<i>Phys. Med. Biol</i>.<b>61</b>R206).

Physics in medicine and biology·2026
Same author

Syndecan-1 Promotes Alveolar Type 2 Epithelial Cell Senescence during Lung Fibrosis.

bioRxiv : the preprint server for biology·2026
Same author

Distinct and cooperative roles of host and tumor Osteopontin in colorectal cancer liver metastasis.

bioRxiv : the preprint server for biology·2026
Same journal

Dual-Function Halide Exchange Strategy for Simultaneous Sn<sup>4+</sup> Elimination and Stability Enhancement in Pb-Sn Mixed Perovskite Solar Cells.

ACS nano·2026
Same journal

Vertically Stacked Indium Gallium Zinc Oxide-Based Three-Dimensional Integrated Circuits.

ACS nano·2026
Same journal

Tunable Nanoparticle Thin-Film Reveals Distance Dependence of Auger-Mediated Radiation Enhancement in Diffuse Midline Glioma.

ACS nano·2026
Same journal

G-Quadruplex Network Engineering in Ionogels: Realizing Robust Biosensing Interfaces for Plant Electrophysiology.

ACS nano·2026
Same journal

Announcing the 2026 <i>ACS Nano</i> Lectureship and <i>ACS Nano</i> Impact Award Laureates.

ACS nano·2026
Same journal

Ultrafast Self-Assembly of Zeolitic Imidazolate Framework-8 Enables Antibody Orientation for Ultrasensitive Lateral Flow Immunoassays.

ACS nano·2026
See all related articles

Related Experiment Video

Updated: Jul 9, 2025

Ameliorating Osteoarthritis in Mice Using Silver Nanoparticles
05:50

Ameliorating Osteoarthritis in Mice Using Silver Nanoparticles

Published on: June 2, 2023

1.2K

Immunomodulatory Nanoparticles for Modulating Arthritis Flares.

Wade T Johnson1, David McBride1, Matthew Kerr1

  • 1Department of NanoEngineering and Chemical Engineering Program, University of California, San Diego, La Jolla, California 92093, United States.

ACS Nano
|November 28, 2023
PubMed
Summary
This summary is machine-generated.

New nanoparticles loaded with calcitriol (CLNP) effectively modulated inflammatory flares in autoimmune joint disorders. These CLNP reduced disease severity and protected joints without causing generalized immune suppression.

Keywords:
antigenarthritisdendritic cellsimmunomodulationnanoparticles

More Related Videos

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

133
Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice
08:43

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice

Published on: January 31, 2020

6.9K

Related Experiment Videos

Last Updated: Jul 9, 2025

Ameliorating Osteoarthritis in Mice Using Silver Nanoparticles
05:50

Ameliorating Osteoarthritis in Mice Using Silver Nanoparticles

Published on: June 2, 2023

1.2K
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

133
Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice
08:43

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice

Published on: January 31, 2020

6.9K

Area of Science:

  • Immunology
  • Nanotechnology
  • Rheumatology

Background:

  • Autoimmune joint disorders like rheumatoid arthritis have improved treatments, but inflammatory flares persist.
  • Current disease-modifying drugs do not fully prevent inflammatory flares, necessitating novel therapeutic strategies.

Purpose of the Study:

  • To develop and evaluate poly(lactic-co-glycolic acid)-poly(ethylene glycol)-maleimide (PLGA-PEG-MAL) nanoparticles conjugated with joint-specific antigens and loaded with calcitriol (CLNP) for modulating autoimmune joint disease flares.
  • To investigate the in vitro and in vivo immunomodulatory effects of CLNP in preclinical models of autoimmune arthritis.

Main Methods:

  • PLGA-PEG-MAL nanoparticles were synthesized, conjugated with aggrecan70-84 and type II bovine collagen256-270 peptides, and loaded with calcitriol.
  • In vitro studies assessed CLNP effects on dendritic cell (DC) phenotype, costimulatory molecule expression, and cytokine production using bulk RNA sequencing.
  • In vivo efficacy was evaluated in collagen-induced arthritis and SKG mouse models, assessing clinical scores, bone erosion, and cartilage preservation via microcomputed tomography and histomorphometry.

Main Results:

  • CLNP demonstrated a hydrodynamic diameter of ~200 nm with low polydispersity.
  • In vitro, CLNP modulated DC phenotype, reducing pro-inflammatory markers and enhancing CTLA-4 expression.
  • In vivo, CLNP accumulated in lymph nodes and significantly reduced clinical scores, bone erosion, and cartilage damage in arthritis models, associated with increased CTLA-4 in joint-infiltrating immune cells.

Conclusions:

  • Calcitriol-loaded nanoparticles (CLNP) effectively mitigate autoimmune joint disease flares in preclinical models.
  • CLNP exert therapeutic effects by modulating immune cell responses, specifically enhancing CTLA-4 expression, without causing broad immunosuppression.
  • These findings support the potential of CLNP as a novel therapeutic approach for managing inflammatory flares in autoimmune arthropathies.